AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01648621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-home monitoring
Description: Tele-home monitoring of SpO2, weight, dyspnea, sputum quantity and characteristics, and general well-being for maximum of 6 months.~Inclusion criteria for tele-home monitoring:~a. compatible phone line b. patient consent c. patient or caregiver demonstrated ability to use monitoring equipment d. patient unable to attend outpatient/community appointments for assessment and monitoring because of environmental barriers to access (e.g. physician's office only accessible by stairs) e. severe dyspnea on activities of daily living (Medical Research Council Questionnaire for Assessing Severity of Breathlessness \[MRC\] Class 4 \& 5 or modified MRC \[mMRC\] 3 \& 4) f. frequent ED visits (> 2) in last 12 months~5. 12 weeks of clinical stability with no ED visits.
Study NCT01648621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated and improved communication
Description: Coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and Community Care Access Centres (CCACs) facilitated by the case manager. This will include phone contact by case manager to family physicians and CCAC case manager if applicable after initial enrollment, education session and development of action plan, then monthly to report general status as well as after subsequent ED presentations/hospital admissions
Study NCT01648621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priority access
Description: Priority access to ambulatory clinics (Respirology and other specialties as required including Psychiatry) facilitated through the case manager.
Study NCT01648621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dictated patient summary
Description: Dictated patient summary sent by specialists (e.g. respirologists) to family physicians following each respiratory centre visit (every 12 weeks)
Study NCT01648621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dictated patient summary
Description: Dictated patient summary sent by specialists (e.g. respirologists) to family physicians following each respiratory centre visit (every 12 weeks)
Study NCT01648621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: in-hospital rehabilitation/self-management program
Description: Referral to an 8 week in-hospital rehabilitation and self-management education program for patients that are:~1. have had a recent exacerbation, but are now clinically stable;~2. symptomatic COPD including reduced activity levels and increased dyspnea despite pharmacological treatment;~3. have stabilized comorbidity (no evidence of active ischemic, musculoskeletal, psychiatric or other systemic disease); and~4. have sufficient motivation to participate.
Study NCT01648621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: in-hospital rehabilitation/self-management program
Description: Referral to an 8 week in-hospital rehabilitation and self-management education program for patients that are:~1. have had a recent exacerbation, but are now clinically stable;~2. symptomatic COPD including reduced activity levels and increased dyspnea despite pharmacological treatment;~3. have stabilized comorbidity (no evidence of active ischemic, musculoskeletal, psychiatric or other systemic disease); and~4. have sufficient motivation to participate.
Study NCT01648621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Referral to a smoking cessation program (as applicable)
Study NCT01648621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation
Description: Referral to a smoking cessation program (as applicable)
Study NCT01648621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action plan Respirologist
Description: Individualized action plan developed with treating respirologist at the discretion of the attending respirologist.
Study NCT01648621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web based self management materials
Description: Referral to educational materials and resources (Living Well with COPD module printouts provided during COPD rehabilitation classes at a cost to the individual)
Study NCT00426426 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioural Therapy
Description: 12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.
Study NCT00426426 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meta-Cognitive Therapy
Description: 12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .
Study NCT00426426 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list
Study NCT00426426 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list
Study NCT01023243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brochure: Care of the Feet for Those at Risk
Description: Patient education materials and key messages for care of the feet for those patients at risk
Study NCT01023243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure: Care of the Feet for Those at Risk
Description: Patient education materials and key messages for care of the feet for those patients at risk
Study NCT01023243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality Survey: foot exam, tobacco and aspirin use
Description: NCQA Patient Survey
Study NCT01023243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality Survey: foot exam, tobacco and aspirin use
Description: NCQA Patient Survey
Study NCT03325543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal instruction and Vaginal palpation
Description: The experimental group will receive verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques and vaginal palpation to learn the correct PFMs contraction. The control group will receive only verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques.
Study NCT03325543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal instruction and Vaginal palpation
Description: The experimental group will receive verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques and vaginal palpation to learn the correct PFMs contraction. The control group will receive only verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques.
Study NCT00094328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bicalutamide
Description: oral
Study NCT00094328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole
Description: oral
Study NCT01876641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib + Cobimetinib, Decitabine
Study NCT02283489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin adenovirus
Description: Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).~Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study.
Study NCT02283489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.
Study NCT02283489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.
Study NCT02821624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor
Study NCT02821624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02402296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: β-1,3/1,6-D-glucan
Description: 15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.
Study NCT02402296 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.
Study NCT00722579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRESILLION cobalt chromium stent
Description: PTCA with bare-metal stent
Study NCT02173730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS
Description: BIBR 1048 MS capsule 150 mg
Study NCT02173730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole tablet 40 mg
Study NCT00817375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI treated group
Description: Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
Study NCT00817375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-SSRI treated group
Description: Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
Study NCT01202487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LET - Lidocaine Epinephrine Tetracaine
Description: One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
Study NCT01202487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LET - Lidocaine Epinephrine Tetracaine
Description: One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
Study NCT01874145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GA 20 mg/mL
Description: Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
Study NCT01874145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA 40 mg/mL
Description: Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
Study NCT03889613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prospective follow-up with videocapsule
Description: prospective follow-up with videocapsule
Study NCT04631705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: Inhaled administration of the human monoclonal antibody DZIF-10c
Study NCT04631705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: Intravenous administration of the human monoclonal antibody DZIF-10c
Study NCT04631705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhalation of DZIF-10c diluent as placebo
Study NCT04631705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
Study NCT04179981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive airway pressure
Description: Positive airway pressure therapy. OVS patients randomized to PAP therapy arm will be titrated to optimal PAP therapy per standard protocol and assigned to use PAP therapy.
Study NCT04179981 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conservative care (control arm)
Description: Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
Study NCT03557086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Care Planning Video Decision Support Tool
Description: Advance care planning video intervention as previously described
Study NCT03557086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Narrative
Description: Verbal description of end of life care options
Study NCT00600379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality system (CAREN™ Integrated Reality System; MOTEK BV, Netherlands).
Description: Training 2/w for 9 weeks (total 18 sessions).
Study NCT00114361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1200 mg a day, 48 weeks
Study NCT00114361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alpha 2a
Description: 180 µg per week, 48 weeks
Study NCT03931447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-72537634
Description: Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule.
Study NCT03931447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as oral capsule in all cohorts.
Study NCT00925535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lersivirine
Description: 1000 mg once daily for 10 days
Study NCT00925535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin
Description: 300 mg once daily for 10 days
Study NCT00925535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: 1000 mg once daily for 10 days
Study NCT00925535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 300 mg once daily for 10 days
Study NCT01653080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced MRI
Description: Studies will be performed on standard clinical MR Systems which are available on Campus. With the proposed imaging technique, we are able to acquire a 3D volume covering the orbit with a temporal resolution of approximately 15s. The affected eye will be immobilized to reduce motion artifacts. A routinely used MR contrast agent will be administered in a dose of 0.1mmol/kg bodyweight.
Study NCT04534114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesomersen sodium (BAY2976217)
Description: Study intervention will be injected subcutaneously.
Study NCT04534114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to BAY2976217 will be injected subcutaneously.
Study NCT01980615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled BGF (PT010) Dose 1
Study NCT01980615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled BGF (PT010) Dose 1
Study NCT01980615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled BGF (PT010) Dose 2
Study NCT01980615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled BGF (PT010) Dose 2
Study NCT01980615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled BGF (PT010) Dose 3
Study NCT01980615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled BGF (PT010) Dose 3
Study NCT01980615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GFF (PT003)
Study NCT01980615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled GFF (PT003)
Study NCT01980615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Symbicort Dose 1
Study NCT01980615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Symbicort Dose 1
Study NCT01980615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Symbicort Dose 2
Study NCT01980615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Symbicort Dose 2
Study NCT01529281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branch Chain Amino Acid (BCAA)
Description: Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with \~300 ml of water.
Study NCT01529281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - asparmate
Description: Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with \~300 ml of water.
Study NCT01984801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% GSK1940029 gel
Description: 200 mg of the gel will be applied to individual patches by using a spatula
Study NCT01984801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% GSK1940029 gel
Description: 200 mg of the gel will be applied to individual patches by using a spatula
Study NCT01984801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3%/1% vehicle gel only
Description: 200 mg of the gel will be applied to individual patches by using a spatula
Study NCT01984801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile distilled water
Description: 200 µL of the solution will be applied to individual patches by using a pipette or syringe
Study NCT01984801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.5% SLS in sterile distilled water
Description: 200 µL of the solution will be applied to individual patches by using a pipette or syringe
Study NCT01984801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.1% SLS in sterile distilled water
Description: 200 µL of the solution will be applied to individual patches by using a pipette or syringe
Study NCT01984801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch only
Description: Only patch will be applied
Study NCT01431040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No bowel prep
Description: Participants in this group will have a regular diet and no bowel prep the day prior surgery up until midnight.
Study NCT01431040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear liquid diet and 2 Fleet's enemas
Description: Participants in this group will receive a clear liquid diet and 2 Fleets enemas in the late afternoon prior to surgery.
Study NCT02543320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LORETA Neurofeedback Training
Description: Undergo LORETA neurofeedback training
Study NCT03528369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGS-200-1
Description: CGS-200-1 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 1% for this study.
Study NCT03528369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGS-200-5
Description: CGS-200-5 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.
Study NCT03528369 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: CGS-200 Vehicle
Description: CGS-200 Vehicle contains all of the ingredients in CGS-200-1 and CGS-200-5 except for capsaicin.
Study NCT02543320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01121198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study NCT01121198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study NCT00621712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GamCath® central venous catheter
Description: choice of catheter type
Study NCT00621712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GamCath Dolphin® Protect central venous catheter
Description: choice of catheter type
Study NCT01838408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ez2go Complete
Description: EZ2Go Complete
Study NCT01838408 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LoSo Prep
Description: LoSo Prep ™ Magnesium Citrate plus Bisacodyl Kit Study Arm
Study NCT04321967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin Paste
Description: 1g of 2% Nitroglycerin paste topical application
Study NCT04321967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dermabond
Description: Topical skin adhesive
Study NCT04321967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermabond
Description: Topical skin adhesive
Study NCT04472377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self sampling kit for collecting discharge from vaginal fornix
Description: A device to collect exfoliative cells from vaginal fornix that can self-operated with ease and comfort.